CORC

在结果中检索

CORC

浏览/检索结果: 共11条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Design and synthesis of novel pyrimidine derivatives as potent antitubercular agents 期刊论文
European Journal of Medicinal Chemistry, 2019, 卷号: Vol.163, 页码: 169-182
作者:  Pingxian Liu;  Yunxiang Tang;  Zhiyong Liu;  Youfu Luo;  Tao Yang
收藏  |  浏览/下载：8/0  |  提交时间：2019/04/24
Design and synthesis of novel pyrimidine derivatives as potent antitubercular agents 期刊论文
European Journal of Medicinal Chemistry, 2019, 卷号: Vol.163, 页码: 169-182
作者:  Pingxian Liu;  Yang Yang;  Yunxiang Tang;  Tao Yang;  Zitai Sang
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/13
Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation 期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 144, 页码: 386-397
作者:  Geng, Kaijun;  Xia, Zongjun;  Ji, Yinchun;  Zhang, Ruisi (Ruthy);  Sun, Deqiao
收藏  |  浏览/下载：155/0  |  提交时间：2019/01/08
ALK-rearranged lung cancer with intradural extramedullary spinal cord metastases responding to ceritinib treatment: A case report 期刊论文
2018, 卷号: 9, 期号: 8, 页码: 1078-1081
作者:  Xu, Yan;  Zhong, Wei;  Chen, Minjiang;  Zhao, Jing;  Wang, Mengzhao
收藏  |  浏览/下载：8/0  |  提交时间：2020/01/03
Drug resistance in ALK-positiveNon-small cell lungcancer patients 期刊论文
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2017, 卷号: 64
作者:  Qian, Mengjia;  Zhu, Bijun;  Wang, Xiangdong;  Liebman, Michael
收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05
Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells 期刊论文
NEOPLASIA, 2016, 卷号: 18, 期号: [db:dc_citation_issue], 页码: 162-171
作者:  Dong, Xuyuan;  Fernandez-Salas, Ester;  Li, Enxiao;  Wang, Shaomeng
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/02
Molecular dynamics simulations reveal the allosteric effect of F1174C resistance mutation to ceritinib in ALK-associated lung cancer 期刊论文
COMPUTATIONAL BIOLOGY AND CHEMISTRY, 2016, 卷号: 65, 页码: 54-60
作者:  Ni, Zhong[1];  Wang, Xiting[2];  Zhang, Tianchen[3];  Jin, Rong Zhong[4]
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/24
ASCEND-6: single-arm, open label, multicenter phase 1/2 study of ceritinib in Chinese pts with advanced ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) previously treated with crizotinib 期刊论文
2016, 卷号: 27
作者:  Zhang, L.;  Shi, Y.;  Tan, D. S. W.;  Hu, B.;  Xiaoqing, L.
收藏  |  浏览/下载：2/0  |  提交时间：2020/01/04
Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer 期刊论文
JOURNAL OF MOLECULAR MODELING, 2015, 卷号: 21, 期号: 7, 页码: 175
作者:  Ni, Zhong[1];  Zhang, Tian-Cheng[2]
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/24
Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance 期刊论文
ACTA PHARMACEUTICA SINICA B, 2015, 卷号: 5, 期号: 1, 页码: 34-37
作者:  Song, Zilan;  Wang, Meining;  Zhang, Ao
收藏  |  浏览/下载：56/0  |  提交时间：2019/01/08

©版权所有 ©2017 CSpace - Powered by CSpace